{"gene":"TRAF3IP2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2000,"finding":"Act1/CIKS (TRAF3IP2) directly interacts with NEMO/IKKγ and activates IKK and SAPK/JNK kinases, functioning as an adaptor that connects upstream signals to NF-κB and AP-1 activation pathways.","method":"Molecular cloning, co-immunoprecipitation, reporter assays, dominant-negative kinase mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — replicated independently by two groups (PMID:10962024 and PMID:10962033) with co-IP and functional reporter assays","pmids":["10962024","10962033"],"is_preprint":false},{"year":2006,"finding":"Act1 (TRAF3IP2) directly associates with IL-17 receptor via homotypic SEFIR domain interaction and is an essential membrane-proximal adaptor for IL-17R signaling, mediating NF-κB activation and inflammatory gene induction.","method":"Co-immunoprecipitation, Act1-deficient fibroblasts, cytokine/chemokine expression assays, NF-κB reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus genetic loss-of-function with defined signaling phenotype, replicated across multiple labs","pmids":["17035243"],"is_preprint":false},{"year":2007,"finding":"After IL-17 stimulation, Act1 is recruited to IL-17R via the SEFIR domain, then recruits TAK1 and the E3 ubiquitin ligase TRAF6 to mediate downstream NF-κB activation. Act1 deficiency abolishes IL-17-induced inflammation in vivo.","method":"Co-immunoprecipitation, Act1-deficient primary astroglial and gut epithelial cells, in vivo EAE and colitis models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, in vitro and in vivo, replicated across labs","pmids":["17277779"],"is_preprint":false},{"year":2000,"finding":"Act1 associates with and activates IκB kinase (IKK), leading to liberation of NF-κB from IκB, and also activates JNK.","method":"cDNA isolation using NF-κB-dependent selectable marker, co-immunoprecipitation, kinase assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical assay, independently replicated","pmids":["10962024"],"is_preprint":false},{"year":2009,"finding":"Act1 is a U-box E3 ubiquitin ligase that, through the Ubc13-Uev1A E2 complex, mediates K63-linked ubiquitination of TRAF6 at lysine-124. U-box mutations abolish this activity and impair IL-17-dependent signaling.","method":"In vitro ubiquitination assay, U-box point mutagenesis, Act1-/- MEF reconstitution, site-directed mutagenesis of TRAF6 K124","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of E3 ligase activity plus mutagenesis of both enzyme and substrate","pmids":["19825828"],"is_preprint":false},{"year":2002,"finding":"Act1 selectively interacts with TRAF6 (but not other TRAF family members) through its N-terminal domain, and this interaction mediates Act1-induced NF-κB activation; IL-1-induced NF-κB is inhibited by excess Act1.","method":"Co-immunoprecipitation, yeast two-hybrid, dominant-negative TRAF6, NF-κB reporter assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — co-IP plus functional reporter with dominant-negative, replicated in subsequent studies","pmids":["12459498"],"is_preprint":false},{"year":2002,"finding":"Act1 is recruited to CD40 receptor in epithelial cells upon CD40L stimulation, interacts with TRAF3, and mediates CD40-induced NF-κB activation and protection from CD40L-induced apoptosis.","method":"Co-immunoprecipitation of endogenous Act1 with CD40, Act1 transfection into Act1-negative C33A cells, NF-κB reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP with endogenous proteins plus gain-of-function reconstitution","pmids":["12089335"],"is_preprint":false},{"year":2004,"finding":"Act1 functions as a negative regulator of CD40- and BAFF-mediated B cell survival; Act1-deficient B cells show enhanced IκB phosphorylation, NF-κB2 processing, and JNK/ERK/p38 activation upon CD40 and BAFF stimulation. Act1 is recruited to CD40 and BAFFR indirectly via TRAF3.","method":"Act1-deficient mice and B cell-specific Act1 KO, Act1/CD40 and Act1/BAFF double-KO epistasis, signaling assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double-KO mice and multiple biochemical signaling readouts","pmids":["15485634"],"is_preprint":false},{"year":2000,"finding":"CIKS/Act1 forms homo-oligomers, interacts with NEMO/IKKγ, and is recruited to the IKK complex upon cell stimulation; oligomerization and IKK recruitment are necessary but not sufficient for NF-κB activation, indicating a second regulatory step.","method":"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple domain deletion mutants with co-IP and functional assays","pmids":["10962033"],"is_preprint":false},{"year":2011,"finding":"Act1/CIKS is essential for all IL-17-induced immediate-early genes in primary fibroblasts. A novel N-terminal subdomain of CIKS is necessary and sufficient for interaction with TRAF6 and NF-κB activation; decoy peptides blocking CIKS-TRAF6 interaction inhibit IL-17 signaling.","method":"Act1-deficient primary mouse embryo fibroblasts, deletion mutagenesis, co-immunoprecipitation, NF-κB reporter, decoy peptide assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — domain mapping, co-IP, and functional decoy peptide with multiple gene expression readouts","pmids":["21335551"],"is_preprint":false},{"year":2011,"finding":"The CC' loop of the Act1 SEFIR domain directly binds IL-17RA and is required for Act1-IL-17RA interaction; deletion of the CC' loop abolishes this interaction. A cell-permeable CC' loop decoy peptide inhibits IL-17- and IL-25-induced pulmonary inflammation in mice.","method":"Deletion mutagenesis, surface plasmon resonance, co-immunoprecipitation, in vivo mouse lung inflammation model","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 — SPR direct binding plus mutagenesis plus in vivo functional validation","pmids":["22045852"],"is_preprint":false},{"year":2013,"finding":"A biallelic T536I missense mutation in the Act1 SEFIR domain in humans abolishes homotypic Act1-IL-17R interaction without affecting Act1 homodimerization, causing failure to respond to IL-17A, IL-17F, and IL-17E, resulting in chronic mucocutaneous candidiasis.","method":"Patient fibroblast signaling assays, co-immunoprecipitation of endogenous proteins, genetic mapping","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — human inborn error with direct biochemical validation of mechanism in patient cells","pmids":["24120361"],"is_preprint":false},{"year":2012,"finding":"The psoriasis-associated Act1 D10N variant is defective in interaction with the molecular chaperone Hsp90, leading to global loss of Act1 function; Act1 is a client protein of Hsp90.","method":"Co-immunoprecipitation of Act1 with Hsp90, Act1-D10N fibroblast signaling assays, Act1-deficient mouse skin phenotype","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — co-IP of client-chaperone interaction, functional validation in patient-variant cells and in vivo mouse model","pmids":["23202271"],"is_preprint":false},{"year":2010,"finding":"The psoriasis-associated coding variant D10N (rs33980500) of TRAF3IP2/Act1 shows reduced binding to TRAF6 in functional assays, suggesting altered modulation of immunoregulatory signals.","method":"Functional binding assays (co-immunoprecipitation), genome-wide association study with functional follow-up","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP binding assay from single study","pmids":["20953186"],"is_preprint":false},{"year":2012,"finding":"TBK1 and IKKi phosphorylate Act1 on serine residues (including Ser311 by IKKi and three additional Ser sites by TBK1), inhibiting Act1-TRAF6 association and consequently suppressing IL-17R-mediated NF-κB activation; TRAF6 (but not TRAF3) is required for IL-17-induced TBK1 activation and its association with Act1.","method":"In vitro kinase assays, site-directed mutagenesis of Ser sites, co-immunoprecipitation, NF-κB reporter","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay plus mutagenesis plus co-IP epistasis","pmids":["22851696"],"is_preprint":false},{"year":2011,"finding":"Persistent IL-17 stimulation induces phosphorylation-dependent Lys48-linked polyubiquitination and degradation of Act1 by SCF(β-TrCP) E3 ubiquitin ligase complexes (containing β-TrCP1 or β-TrCP2), providing a desensitization mechanism for IL-17R signaling.","method":"Co-immunoprecipitation, dominant-negative β-TrCP, siRNA knockdown, ubiquitination assays in HeLa cells","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, dominant-negative, and siRNA with multiple orthogonal readouts","pmids":["22045853"],"is_preprint":false},{"year":2018,"finding":"Act1 binds and stabilizes inflammatory mRNAs (e.g., Cxcl1) through its SEFIR domain binding to a stem-loop structure (SEFIR-binding element, SBE) in the 3'UTR. Act1 assembles three distinct RNA-protein complexes (RNPs) that prevent mRNA decay in the nucleus, inhibit decapping in P bodies, and promote translation.","method":"RNA immunoprecipitation, RNA aptamer competition, Act1 SEFIR domain-RNA binding assays, fractionation, in vivo mouse inflammation models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — direct RNA-protein binding assay, multiple RNP characterization methods, in vivo aptamer validation","pmids":["29563620"],"is_preprint":false},{"year":2013,"finding":"HuR RNA-binding protein is required for IL-17-induced Act1-mediated mRNA stabilization of CXCL1 and CXCL5; Act1 mediates K63-linked polyubiquitination of HuR, which is required for HuR binding to CXCL1 mRNA and for mRNA stabilization.","method":"HuR-deficient cells, co-immunoprecipitation, sucrose gradient polysome fractionation, HuR lung epithelial deletion mouse model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic and biochemical dissection of ubiquitination event with in vivo validation","pmids":["23772036"],"is_preprint":false},{"year":2014,"finding":"The SEFIR domain of IL-17RA has a 2.3 Å crystal structure; helix αC within the SEFIR domain is critical for interaction with Act1 and IL-17-stimulated gene expression, establishing that heterotypic SEFIR-SEFIR interaction via αC helix is the conserved mechanism for IL-17 signaling.","method":"X-ray crystallography (2.3 Å), mutagenesis of αC helix, gene expression assay","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional mutagenesis","pmids":["24816115"],"is_preprint":false},{"year":2003,"finding":"CIKS/Act1 forms homo-oligomers and requires a second level of regulation beyond NEMO/IKKγ binding for NF-κB activation; a deletion mutant that oligomerizes and binds NEMO but lacks the additional region fails to activate NF-κB.","method":"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — single lab with domain mapping and co-IP, moderate evidence","pmids":["12943667"],"is_preprint":false},{"year":2009,"finding":"Act1 is an essential signaling molecule for IL-25 (IL-17E) receptor signaling; Act1 deficiency abolishes IL-25-induced Th2 cytokine expression and pulmonary eosinophilia, and Act1 in epithelial cells is required for both IL-17-induced neutrophilia and IL-25-induced eosinophilia.","method":"Act1-deficient mice, epithelial cell-specific Act1 knockout, allergic pulmonary inflammation model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic deletion with defined cellular phenotype, replicated by two independent groups","pmids":["19155512","19155511"],"is_preprint":false},{"year":2010,"finding":"Act1 in neuroectoderm-derived CNS-resident cells (specifically astrocytes and NG2+ glia) is required for IL-17-mediated recruitment of lymphocytes, neutrophils, and macrophages in EAE; Act1 deficiency in astrocytes impairs IL-17-mediated inflammatory gene induction.","method":"Cell-type-specific conditional Act1 knockout mice, EAE model, inflammatory mediator expression assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — conditional cell-type-specific KO with defined in vivo phenotype, replicated","pmids":["20303295","23995070"],"is_preprint":false},{"year":2009,"finding":"The Chlamydia pneumoniae inclusion membrane protein CP0236 binds directly to Act1, sequesters Act1 away from the IL-17 receptor upon IL-17A stimulation, and thereby inhibits NF-κB activation in infected cells.","method":"Yeast two-hybrid, co-immunoprecipitation of ectopic CP0236 with endogenous Act1, immunofluorescence localization, NF-κB activation assay","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with endogenous protein plus functional signaling readout, single lab","pmids":["19159390"],"is_preprint":false},{"year":2021,"finding":"FYN-TRAF3IP2 is a recurrent oncogenic gene fusion in angioimmunoblastic T cell lymphoma and PTCL-NOS that leads to aberrant NF-κB signaling downstream of T cell receptor activation; expression in hematopoietic progenitors induces NF-κB-driven T cell transformation in mice.","method":"RNA sequencing fusion discovery, hematopoietic progenitor transduction mouse model, IKK inhibitor treatment in vitro and in vivo","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse model plus pharmacologic IKK inhibition, replicated in independent cohort","pmids":["33928261"],"is_preprint":false},{"year":2021,"finding":"FYN-TRAF3IP2 and KHDRBS1-LCK fusions activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinical drugs targeting these pathways.","method":"RNA sequencing, ex vivo and in vivo experiments in PTCL models","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — ex vivo and in vivo functional validation, single lab","pmids":["34140493"],"is_preprint":false},{"year":2018,"finding":"Act1 functions as a negative regulator in T and B cells via direct inhibition of STAT3; Act1 deficiency (but not Il17ra, Il17rc, or Il17rb deficiency) results in hyper IL-23- and IL-21-induced STAT3 activation. Mass spectrometry detected an Act1-STAT3 complex.","method":"Mass spectrometry (interactome), STAT3 activation assays in Act1-/- and single receptor KO T and B cells, in vivo autoimmune disease models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — MS-identified complex, genetic epistasis with multiple receptor KOs, defined signaling phenotype","pmids":["30013031"],"is_preprint":false},{"year":2014,"finding":"Syk kinase is an upstream regulator in IL-17A signaling; Syk interacts with TRAF6 and Act1 under IL-17A stimulation, and Syk inhibition diminishes Act1-TRAF6 interaction and TRAF6 K63-linked polyubiquitination, reducing CCL20 expression in keratinocytes.","method":"Co-immunoprecipitation, siRNA knockdown, pharmacological Syk inhibition, ubiquitination assay, promoter activity assay","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus functional epistasis, single lab","pmids":["25202827"],"is_preprint":false},{"year":2015,"finding":"IL-17 stimulation promotes formation of a CIKS/Act1-DDX3X complex requiring the DDX3X helicase domain (but not its ATPase activity); this complex stabilizes Zc3h12a mRNA. IKKε, TRAF2, and TRAF5 are also required for this IL-17-induced mRNA stabilization.","method":"Co-immunoprecipitation, DDX3X knockdown, mRNA stability assays, direct RNA-binding assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus direct RNA binding plus functional mRNA stability readout, single lab","pmids":["25710910"],"is_preprint":false},{"year":2014,"finding":"TRAF3IP2 mediates oxLDL-induced endothelial cell death via Nox2/superoxide-dependent upregulation of TRAF3IP2, IKK/p65, and JNK/c-Jun activation; TRAF3IP2 knockdown attenuates this death and vasorelaxation impairment ex vivo.","method":"siRNA knockdown, Nox2 inhibition, ex vivo aortic ring relaxation, cell death assays","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — siRNA plus pharmacological inhibition with defined phenotypic readout, single lab","pmids":["24561578"],"is_preprint":false},{"year":2012,"finding":"CIKS/TRAF3IP2 mediates angiotensin-II-induced IKK/NF-κB and JNK/AP-1 activation in cardiomyocytes, functioning as a scaffold protein binding to IKK and JNK; CIKS-null mice are protected from Ang-II-induced cardiac hypertrophy and fibrosis despite similar blood pressure increases.","method":"CIKS-null mice, co-immunoprecipitation (CIKS binding to IKK and JNK), siRNA, Ang-II infusion in vivo","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with in vivo cardiac phenotype plus biochemical scaffold function via co-IP","pmids":["22575763"],"is_preprint":false},{"year":2011,"finding":"Act1 in IL-17 signaling promotes osteoclastogenesis by stimulating RANKL expression in osteoblastic cells; this requires both the E3 ligase U-box and the SEFIR domain of Act1. Act1-deficient mice are protected from ovariectomy-induced bone loss.","method":"Act1-/- mice, osteoblast-specific Act1 reconstitution with U-box and SEFIR domain mutants, RANKL expression assay, ovariectomy bone loss model","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 2 — domain mutagenesis reconstitution in KO cells plus in vivo disease model","pmids":["22511335"],"is_preprint":false},{"year":2011,"finding":"Act1 expression in T cells is required for IL-25-driven Th2 polarization (but not conventional IL-4-driven polarization), including induction of GATA-3 and GFI-1 transcription factors, eosinophilic airway infiltration, and airway hyperresponsiveness.","method":"T cell-specific Act1-deficient mice, IL-25 stimulation, Th2 differentiation assays, airway inflammation model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic deletion with defined cellular and molecular phenotype","pmids":["21856933"],"is_preprint":false},{"year":2022,"finding":"IL-17A stimulation recruits MST1 to ACT1 in keratinocytes, reducing MST1-LATS1 interaction and leading to YAP dephosphorylation and activation of the YAP-AREG axis promoting keratinocyte proliferation.","method":"Co-immunoprecipitation (MST1 with ACT1), immunofluorescence, siRNA knockdown, HaCaT and primary keratinocyte assays","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP of endogenous proteins plus siRNA functional assay, single lab","pmids":["35304250"],"is_preprint":false},{"year":2019,"finding":"IL-17A induces Act1/FADD-dependent caspase-mediated apoptosis in retinal endothelial cells, contributing to retinal capillary degeneration in diabetes; IL-17A-/- mice show significantly less retinal capillary degeneration.","method":"IL-17A-/- diabetic mouse model, ex vivo retinal endothelial cell signaling assays, caspase assay","journal":"Journal of diabetes and its complications","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic KO mouse model plus ex vivo signaling dissection, single lab","pmids":["31239234"],"is_preprint":false},{"year":2011,"finding":"Act1 is an evolutionarily conserved signaling protein; zebrafish Act1 retains TRAF6 binding and NF-κB activation capacity in human cells, and a highly conserved N-terminal motif is critical for TRAF6 binding. The helix-loop-helix and Ufd2-box domains enabling JNK activation have more recent evolutionary origins in higher vertebrates.","method":"Evolutionary sequence analysis, zebrafish Act1 expression in human cells, co-immunoprecipitation, NF-κB and JNK reporter assays","journal":"Journal of molecular evolution","confidence":"Medium","confidence_rationale":"Tier 2-3 — cross-species functional complementation with reporter assays, single lab","pmids":["21643828"],"is_preprint":false},{"year":2021,"finding":"The antisense lncRNA TRAF3IP2-AS1 regulates Act1 expression and IL-17A signaling by recruiting SRSF10, which downregulates IRF1, a transcriptional activator of Act1; a psoriasis-susceptible variant A4165G (rs13210247) of TRAF3IP2-AS1 is a gain-of-function mutant that increases Act1 expression.","method":"lncRNA knockdown/overexpression, SRSF10 siRNA, IRF1 ChIP, Act1 promoter reporter assay, mouse psoriasis and EAE models","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple molecular methods, single lab, in vivo therapeutic validation","pmids":["33941656"],"is_preprint":false},{"year":2014,"finding":"Human ACT1 undergoes alternative splicing producing two isoforms; both are Hsp90 client proteins, but ACT1-D19N has an additional Hsp90 binding site from the nine extra amino acids absent in ACT1-D10N. ACT1-D10N fails to transduce IL-17 signals, while ACT1-D19N is fully responsive. The two isoforms are differentially expressed in fibroblasts versus T cells.","method":"Co-immunoprecipitation with Hsp90, IL-17 signaling assays in ACT1(D10N/D10N) fibroblasts and T cells, isoform-specific expression analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP and signaling assays in human cells with variant proteins, single lab","pmids":["25024377"],"is_preprint":false}],"current_model":"TRAF3IP2/Act1 is a multifunctional cytoplasmic adaptor and U-box E3 ubiquitin ligase that serves as the essential membrane-proximal transducer for IL-17 receptor family signaling: upon IL-17 stimulation, its SEFIR domain (via the CC' loop/αC helix) mediates heterotypic interaction with the IL-17R SEFIR domain, whereupon Act1 recruits TRAF6 (via a conserved N-terminal motif) and mediates K63-linked ubiquitination of TRAF6 to activate TAK1/IKK/NF-κB and JNK/AP-1 pathways; Act1 also directly stabilizes select inflammatory mRNAs by binding 3'UTR stem-loop structures and assembling RNPs; it is regulated by Hsp90 chaperoning, phosphorylation by TBK1/IKKi (which suppresses TRAF6 interaction), and SCF(β-TrCP)-mediated K48-ubiquitin degradation for signal termination; additionally, Act1 acts as a negative regulator in B cells (downstream of CD40/BAFF via TRAF3) and directly inhibits STAT3 in T and B cells, while the oncogenic FYN-TRAF3IP2 fusion drives aberrant NF-κB signaling in peripheral T cell lymphomas."},"narrative":{"teleology":[{"year":2000,"claim":"Identification of TRAF3IP2/Act1 as a novel NF-κB- and JNK-activating adaptor established the gene as a signaling node upstream of IKK, resolving whether it was merely a scaffold or an active signal inducer.","evidence":"Molecular cloning, co-immunoprecipitation with NEMO/IKKγ, NF-κB and JNK reporter assays by two independent groups","pmids":["10962024","10962033"],"confidence":"High","gaps":["Upstream receptor triggering Act1 was unknown","Enzymatic activity of Act1 itself not characterized","Homo-oligomerization shown but second regulatory step undefined"]},{"year":2002,"claim":"Demonstration that Act1 selectively binds TRAF6 (not other TRAFs) through its N-terminus and participates in CD40 signaling via TRAF3 placed it at the intersection of TNF-family and NF-κB pathways, narrowing the search for its functional partnerships.","evidence":"Yeast two-hybrid and co-immunoprecipitation of Act1 with TRAF6 and TRAF3; CD40-induced recruitment of endogenous Act1 in epithelial cells","pmids":["12459498","12089335"],"confidence":"High","gaps":["Physiological receptor linking Act1 to innate immunity remained unknown","Whether Act1 had E3 ligase activity was not tested"]},{"year":2004,"claim":"Genetic evidence from Act1-deficient mice revealed an unexpected negative regulatory role in B cells downstream of CD40 and BAFF via TRAF3, resolving conflicting positive/negative functions into a cell-type-dependent model.","evidence":"Act1-KO mice and B-cell-specific conditional KO; Act1/CD40 and Act1/BAFF double-KO epistasis","pmids":["15485634"],"confidence":"High","gaps":["Molecular mechanism of negative regulation in B cells was unclear","IL-17 receptor connection not yet established"]},{"year":2006,"claim":"Discovery that Act1 directly binds IL-17R via homotypic SEFIR domain interaction and is indispensable for IL-17-induced NF-κB activation identified the long-sought obligate adaptor connecting IL-17 family receptors to downstream inflammatory signaling.","evidence":"Co-immunoprecipitation of Act1 with IL-17R, Act1-deficient fibroblasts showing abolished IL-17 responses","pmids":["17035243"],"confidence":"High","gaps":["Structural basis of SEFIR–SEFIR interaction unknown","E3 ligase activity of Act1 not yet recognized"]},{"year":2007,"claim":"In vivo validation using Act1-deficient mice in EAE and colitis models established that Act1-dependent recruitment of TRAF6 and TAK1 to IL-17R is required for inflammatory disease, cementing Act1 as a therapeutic target.","evidence":"Act1-KO primary cells plus EAE and dextran sulfate colitis in vivo models","pmids":["17277779"],"confidence":"High","gaps":["Precise ubiquitination substrate and linkage type downstream of Act1 unknown","Role in IL-25 signaling not yet tested"]},{"year":2009,"claim":"Biochemical reconstitution showed Act1 is a U-box E3 ubiquitin ligase that catalyzes K63-linked ubiquitination of TRAF6 at K124, resolving whether Act1 was merely an adaptor or an active enzyme in IL-17 signaling.","evidence":"In vitro ubiquitination assay with Ubc13–Uev1A, U-box point mutations, TRAF6 K124R mutagenesis, reconstitution in Act1−/− MEFs","pmids":["19825828"],"confidence":"High","gaps":["Whether Act1 ubiquitinates additional substrates beyond TRAF6 was unknown","Structural basis of U-box activity not determined"]},{"year":2009,"claim":"Extension of Act1's adaptor role to IL-25 (IL-17E) receptor signaling demonstrated that Act1 is a universal transducer for the entire IL-17 receptor family, broadening its function from Th17 to Th2 immunity.","evidence":"Act1-KO and epithelial-specific Act1-KO mice in IL-25-driven pulmonary eosinophilia models","pmids":["19155512","19155511"],"confidence":"High","gaps":["Whether Act1 uses distinct downstream effectors for IL-25 versus IL-17A was unclear"]},{"year":2011,"claim":"Structural and peptide-decoy studies mapped the CC' loop of the Act1 SEFIR domain as the critical interface for IL-17RA binding, and identified a conserved N-terminal subdomain sufficient for TRAF6 interaction, providing a molecular framework for therapeutic intervention.","evidence":"SPR direct binding, deletion mutagenesis, cell-permeable CC' loop decoy peptide blocking pulmonary inflammation in mice","pmids":["22045852","21335551"],"confidence":"High","gaps":["High-resolution co-crystal structure of Act1–IL-17RA complex not available","SEFIR domain structure of Act1 itself unsolved"]},{"year":2011,"claim":"Identification of SCF(β-TrCP)-mediated K48-linked ubiquitination and proteasomal degradation of Act1 upon persistent IL-17 stimulation revealed the signal-termination mechanism for IL-17R pathway desensitization.","evidence":"Co-immunoprecipitation with β-TrCP1/2, dominant-negative β-TrCP, siRNA, ubiquitination assays in HeLa cells","pmids":["22045853"],"confidence":"High","gaps":["Phosphodegron on Act1 recognized by β-TrCP not precisely mapped","Kinase responsible for degron phosphorylation not identified"]},{"year":2012,"claim":"Discovery that TBK1/IKKi phosphorylate Act1 on multiple serine residues to inhibit TRAF6 binding established a negative feedback loop within IL-17 signaling, explaining how cells attenuate inflammatory output.","evidence":"In vitro kinase assays, site-directed Ser mutagenesis, co-IP showing reduced Act1–TRAF6 association","pmids":["22851696"],"confidence":"High","gaps":["Temporal dynamics of phosphorylation-dependent versus degradation-dependent attenuation not resolved"]},{"year":2012,"claim":"Identification of Act1 as an Hsp90 client protein, with the psoriasis-associated D10N variant defective in Hsp90 binding, provided the first mechanism linking a TRAF3IP2 disease-associated variant to protein stability and global loss of function.","evidence":"Co-IP of Act1 with Hsp90, D10N fibroblast signaling assays, Act1-deficient mouse skin phenotype","pmids":["23202271"],"confidence":"High","gaps":["Whether alternative isoform D19N fully compensates in all tissues was only partially resolved"]},{"year":2013,"claim":"Identification of a human biallelic T536I SEFIR domain mutation abolishing Act1–IL-17R interaction and causing chronic mucocutaneous candidiasis provided direct genetic proof that Act1 is essential for human anti-fungal immunity.","evidence":"Patient fibroblast signaling assays, co-IP of endogenous proteins, genetic mapping in affected kindred","pmids":["24120361"],"confidence":"High","gaps":["Whether T536I affects Act1's RNA-binding or STAT3-inhibitory functions was not examined"]},{"year":2013,"claim":"Demonstration that Act1 mediates K63-linked ubiquitination of HuR to promote inflammatory mRNA stabilization revealed a post-transcriptional effector arm beyond NF-κB, expanding Act1's mechanistic repertoire.","evidence":"HuR-deficient cells, co-IP, polysome fractionation, HuR lung-epithelial deletion mouse model","pmids":["23772036"],"confidence":"High","gaps":["Full repertoire of mRNA targets stabilized by Act1–HuR axis unknown"]},{"year":2018,"claim":"Discovery that Act1's SEFIR domain directly binds stem-loop structures (SBEs) in inflammatory mRNA 3′UTRs and assembles three distinct RNP complexes for nuclear stabilization, P-body decapping inhibition, and translational promotion established Act1 as a bona fide RNA-binding protein.","evidence":"RNA immunoprecipitation, RNA aptamer competition, SEFIR domain–RNA binding assays, in vivo aptamer-based inhibition in mouse inflammation models","pmids":["29563620"],"confidence":"High","gaps":["Structural basis of SEFIR–RNA interaction unsolved","Full transcriptome-wide set of SBE-containing targets not defined"]},{"year":2018,"claim":"Demonstration that Act1 directly inhibits STAT3 in T and B cells independently of IL-17 receptors resolved the paradox of why Act1-KO but not IL-17R-KO mice develop autoimmunity, establishing a dual positive/negative regulatory logic.","evidence":"Mass spectrometry identifying Act1–STAT3 complex, STAT3 phosphorylation assays in Act1−/− and receptor-KO T and B cells, autoimmune disease models","pmids":["30013031"],"confidence":"High","gaps":["Molecular mechanism of STAT3 inhibition (direct binding site, competition, or sequestration) not delineated"]},{"year":2021,"claim":"Discovery of the recurrent FYN-TRAF3IP2 oncogenic fusion in peripheral T-cell lymphomas demonstrated that constitutive Act1-driven NF-κB activation is sufficient for T-cell transformation, directly implicating the gene in cancer pathogenesis.","evidence":"RNA-seq fusion detection, hematopoietic progenitor transduction in mouse model, IKK inhibitor rescue in vitro and in vivo","pmids":["33928261","34140493"],"confidence":"High","gaps":["Whether the fusion retains Act1's RNA-binding or STAT3-inhibitory functions is unknown","Frequency of FYN-TRAF3IP2 across broader lymphoma subtypes incompletely characterized"]},{"year":null,"claim":"Key unresolved questions include the high-resolution structure of the Act1 SEFIR domain and its interface with IL-17RA, the full transcriptome of SBE-containing mRNAs regulated by Act1, the molecular mechanism by which Act1 inhibits STAT3, and whether Act1's E3 ligase activity extends to substrates beyond TRAF6 and HuR.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of Act1 itself","Transcriptome-wide CLIP-seq of Act1 RNA targets not performed","STAT3 inhibition mechanism not biochemically reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[4,17,30]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,2,5,8,9]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[16,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,25]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1,2,8]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,20,21,31]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,7,25,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,23,24]}],"complexes":["IL-17R signalosome (Act1–IL-17RA–IL-17RC)","Act1–TRAF6 complex"],"partners":["TRAF6","TRAF3","NEMO","IL17RA","HSP90","STAT3","DDX3X","ELAVL1"],"other_free_text":[]},"mechanistic_narrative":"TRAF3IP2 (Act1/CIKS) is a cytoplasmic adaptor and U-box E3 ubiquitin ligase that functions as the obligate membrane-proximal signal transducer for IL-17 family receptor signaling and additionally acts as a negative regulator of CD40/BAFF and STAT3 pathways in lymphocytes. Upon IL-17 stimulation, Act1 is recruited to IL-17R via heterotypic SEFIR domain interaction (mediated by the CC' loop/αC helix), then recruits TRAF6 through a conserved N-terminal motif and catalyzes K63-linked ubiquitination of TRAF6 at K124 via the Ubc13–Uev1A E2 complex, activating downstream TAK1/IKK/NF-κB and JNK/AP-1 cascades [PMID:17035243, PMID:19825828, PMID:22045852]. Act1 also directly binds stem-loop structures in inflammatory mRNA 3′UTRs through its SEFIR domain, assembling distinct ribonucleoprotein complexes that prevent mRNA decay and promote translation, while its own turnover is governed by Hsp90 chaperoning, TBK1/IKKi-mediated inhibitory phosphorylation, and SCF(β-TrCP)-dependent K48-linked ubiquitination and degradation [PMID:29563620, PMID:23202271, PMID:22851696, PMID:22045853]. Biallelic loss-of-function mutation (T536I) in the SEFIR domain abolishes IL-17R interaction and causes chronic mucocutaneous candidiasis in humans, while the FYN-TRAF3IP2 fusion drives NF-κB-dependent T-cell lymphomagenesis [PMID:24120361, PMID:33928261]."},"prefetch_data":{"uniprot":{"accession":"O43734","full_name":"E3 ubiquitin ligase TRAF3IP2","aliases":["Adapter protein CIKS","Connection to IKK and SAPK/JNK","E3 ubiquitin-protein ligase CIKS","Nuclear factor NF-kappa-B activator 1","ACT1","TRAF3-interacting protein 2"],"length_aa":574,"mass_kda":64.7,"function":"E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O43734/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAF3IP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRAF3IP2","total_profiled":1310},"omim":[{"mim_id":"615527","title":"CANDIDIASIS, FAMILIAL, 8; CANDF8","url":"https://www.omim.org/entry/615527"},{"mim_id":"614995","title":"INTERLEUKIN 17 RECEPTOR E; IL17RE","url":"https://www.omim.org/entry/614995"},{"mim_id":"614070","title":"PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13","url":"https://www.omim.org/entry/614070"},{"mim_id":"611831","title":"MITOCHONDRIAL RIBOSOMAL PROTEIN L18; MRPL18","url":"https://www.omim.org/entry/611831"},{"mim_id":"608004","title":"NUCLEAR FACTOR KAPPA-B INHIBITOR, ZETA; NFKBIZ","url":"https://www.omim.org/entry/608004"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAF3IP2"},"hgnc":{"alias_symbol":["DKFZP586G0522","ACT1","CIKS"],"prev_symbol":["C6orf4","C6orf5","C6orf6","C6orf2"]},"alphafold":{"accession":"O43734","domains":[{"cath_id":"3.40.50.11530","chopping":"408-554","consensus_level":"high","plddt":86.2789,"start":408,"end":554}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43734","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43734-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43734-F1-predicted_aligned_error_v6.png","plddt_mean":53.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAF3IP2","jax_strain_url":"https://www.jax.org/strain/search?query=TRAF3IP2"},"sequence":{"accession":"O43734","fasta_url":"https://rest.uniprot.org/uniprotkb/O43734.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43734/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43734"}},"corpus_meta":[{"pmid":"17277779","id":"PMC_17277779","title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.","date":"2007","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17277779","citation_count":499,"is_preprint":false},{"pmid":"9055993","id":"PMC_9055993","title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.","date":"1997","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/9055993","citation_count":366,"is_preprint":false},{"pmid":"1427032","id":"PMC_1427032","title":"Systematic mutational analysis of the yeast ACT1 gene.","date":"1992","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1427032","citation_count":306,"is_preprint":false},{"pmid":"20953186","id":"PMC_20953186","title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20953186","citation_count":298,"is_preprint":false},{"pmid":"20953188","id":"PMC_20953188","title":"Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20953188","citation_count":297,"is_preprint":false},{"pmid":"17035243","id":"PMC_17035243","title":"Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17035243","citation_count":297,"is_preprint":false},{"pmid":"20303295","id":"PMC_20303295","title":"Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.","date":"2010","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20303295","citation_count":238,"is_preprint":false},{"pmid":"24120361","id":"PMC_24120361","title":"An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24120361","citation_count":229,"is_preprint":false},{"pmid":"19825828","id":"PMC_19825828","title":"Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19825828","citation_count":193,"is_preprint":false},{"pmid":"23995070","id":"PMC_23995070","title":"Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells.","date":"2013","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23995070","citation_count":180,"is_preprint":false},{"pmid":"17982039","id":"PMC_17982039","title":"Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17982039","citation_count":179,"is_preprint":false},{"pmid":"9227855","id":"PMC_9227855","title":"Actin in the parasite Toxoplasma gondii is encoded by a single copy gene, ACT1 and exists primarily in a globular form.","date":"1997","source":"Cell motility and the cytoskeleton","url":"https://pubmed.ncbi.nlm.nih.gov/9227855","citation_count":154,"is_preprint":false},{"pmid":"10962024","id":"PMC_10962024","title":"Act1, an NF-kappa B-activating protein.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10962024","citation_count":145,"is_preprint":false},{"pmid":"1753941","id":"PMC_1753941","title":"Construction of expression vectors based on the rice actin 1 (Act1) 5' region for use in monocot transformation.","date":"1991","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/1753941","citation_count":143,"is_preprint":false},{"pmid":"10962033","id":"PMC_10962033","title":"CIKS, a connection to Ikappa B kinase and stress-activated protein kinase.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10962033","citation_count":132,"is_preprint":false},{"pmid":"21335551","id":"PMC_21335551","title":"IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21335551","citation_count":125,"is_preprint":false},{"pmid":"10463153","id":"PMC_10463153","title":"Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences.","date":"1999","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10463153","citation_count":121,"is_preprint":false},{"pmid":"1821763","id":"PMC_1821763","title":"Analysis of rice Act1 5' region activity in transgenic rice plants.","date":"1991","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/1821763","citation_count":118,"is_preprint":false},{"pmid":"15485634","id":"PMC_15485634","title":"Act1, a negative regulator in CD40- and BAFF-mediated B cell survival.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15485634","citation_count":114,"is_preprint":false},{"pmid":"19155512","id":"PMC_19155512","title":"The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19155512","citation_count":114,"is_preprint":false},{"pmid":"19155511","id":"PMC_19155511","title":"The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19155511","citation_count":113,"is_preprint":false},{"pmid":"24561578","id":"PMC_24561578","title":"OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators.","date":"2014","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24561578","citation_count":104,"is_preprint":false},{"pmid":"29563620","id":"PMC_29563620","title":"IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29563620","citation_count":101,"is_preprint":false},{"pmid":"33160017","id":"PMC_33160017","title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/33160017","citation_count":96,"is_preprint":false},{"pmid":"31862399","id":"PMC_31862399","title":"Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31862399","citation_count":94,"is_preprint":false},{"pmid":"22511335","id":"PMC_22511335","title":"IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22511335","citation_count":90,"is_preprint":false},{"pmid":"23202271","id":"PMC_23202271","title":"The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23202271","citation_count":90,"is_preprint":false},{"pmid":"22744010","id":"PMC_22744010","title":"Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.","date":"2012","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/22744010","citation_count":89,"is_preprint":false},{"pmid":"23772036","id":"PMC_23772036","title":"HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23772036","citation_count":87,"is_preprint":false},{"pmid":"8597657","id":"PMC_8597657","title":"Conserved expression of the Arabidopsis ACT1 and ACT 3 actin subclass in organ primordia and mature pollen.","date":"1996","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/8597657","citation_count":86,"is_preprint":false},{"pmid":"30528823","id":"PMC_30528823","title":"Neutrophil Extracellular Traps Induce Human Th17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30528823","citation_count":85,"is_preprint":false},{"pmid":"22851696","id":"PMC_22851696","title":"TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22851696","citation_count":77,"is_preprint":false},{"pmid":"27980343","id":"PMC_27980343","title":"IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling.","date":"2016","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27980343","citation_count":76,"is_preprint":false},{"pmid":"36411467","id":"PMC_36411467","title":"Salidroside attenuates HALI via IL-17A-mediated ferroptosis of alveolar epithelial cells by regulating Act1-TRAF6-p38 MAPK pathway.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/36411467","citation_count":74,"is_preprint":false},{"pmid":"22608496","id":"PMC_22608496","title":"Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) innate cell population.","date":"2012","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22608496","citation_count":61,"is_preprint":false},{"pmid":"12574281","id":"PMC_12574281","title":"Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases.","date":"2003","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/12574281","citation_count":61,"is_preprint":false},{"pmid":"18061473","id":"PMC_18061473","title":"Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18061473","citation_count":60,"is_preprint":false},{"pmid":"22699909","id":"PMC_22699909","title":"IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22699909","citation_count":57,"is_preprint":false},{"pmid":"18624351","id":"PMC_18624351","title":"Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18624351","citation_count":57,"is_preprint":false},{"pmid":"25202827","id":"PMC_25202827","title":"Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.","date":"2014","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25202827","citation_count":56,"is_preprint":false},{"pmid":"28476142","id":"PMC_28476142","title":"Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.","date":"2017","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/28476142","citation_count":55,"is_preprint":false},{"pmid":"33741027","id":"PMC_33741027","title":"Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33741027","citation_count":55,"is_preprint":false},{"pmid":"26148936","id":"PMC_26148936","title":"Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26148936","citation_count":53,"is_preprint":false},{"pmid":"25881004","id":"PMC_25881004","title":"Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25881004","citation_count":53,"is_preprint":false},{"pmid":"23453926","id":"PMC_23453926","title":"Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling.","date":"2013","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23453926","citation_count":52,"is_preprint":false},{"pmid":"24892823","id":"PMC_24892823","title":"Interleukin-17A promotes MUC5AC expression and goblet cell hyperplasia in nasal polyps via the Act1-mediated pathway.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24892823","citation_count":51,"is_preprint":false},{"pmid":"23836313","id":"PMC_23836313","title":"TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.","date":"2013","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23836313","citation_count":50,"is_preprint":false},{"pmid":"22575763","id":"PMC_22575763","title":"CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy.","date":"2012","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22575763","citation_count":49,"is_preprint":false},{"pmid":"12089335","id":"PMC_12089335","title":"Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12089335","citation_count":49,"is_preprint":false},{"pmid":"22045853","id":"PMC_22045853","title":"Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22045853","citation_count":47,"is_preprint":false},{"pmid":"35304250","id":"PMC_35304250","title":"IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP-AREG Axis.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35304250","citation_count":46,"is_preprint":false},{"pmid":"22045852","id":"PMC_22045852","title":"A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22045852","citation_count":46,"is_preprint":false},{"pmid":"8243992","id":"PMC_8243992","title":"Screens for extragenic mutations that fail to complement act1 alleles identify genes that are important for actin function in Saccharomyces cerevisiae.","date":"1993","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8243992","citation_count":46,"is_preprint":false},{"pmid":"22445837","id":"PMC_22445837","title":"TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.","date":"2012","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/22445837","citation_count":44,"is_preprint":false},{"pmid":"12023082","id":"PMC_12023082","title":"Chromosomal ampC genes in Enterobacter species other than Enterobacter cloacae, and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae.","date":"2002","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12023082","citation_count":40,"is_preprint":false},{"pmid":"23085260","id":"PMC_23085260","title":"CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23085260","citation_count":39,"is_preprint":false},{"pmid":"16524910","id":"PMC_16524910","title":"The actin gene ACT1 is required for phagocytosis, motility, and cell separation of Tetrahymena thermophila.","date":"2006","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/16524910","citation_count":39,"is_preprint":false},{"pmid":"21856933","id":"PMC_21856933","title":"T cell-derived Act1 is necessary for IL-25-mediated Th2 responses and allergic airway inflammation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21856933","citation_count":38,"is_preprint":false},{"pmid":"12459498","id":"PMC_12459498","title":"NF-kappaB activator Act1 associates with IL-1/Toll pathway adaptor molecule TRAF6.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12459498","citation_count":38,"is_preprint":false},{"pmid":"19407614","id":"PMC_19407614","title":"The connexin43 carboxyl-terminal peptide ACT1 modulates the biological response to silicone implants.","date":"2009","source":"Plastic and reconstructive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19407614","citation_count":37,"is_preprint":false},{"pmid":"30989715","id":"PMC_30989715","title":"microRNA-340-5p inhibits hypoxia/reoxygenation-induced apoptosis and oxidative stress in cardiomyocytes by regulating the Act1/NF-κB pathway.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30989715","citation_count":36,"is_preprint":false},{"pmid":"30013031","id":"PMC_30013031","title":"Act1 is a negative regulator in T and B cells via direct inhibition of STAT3.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30013031","citation_count":36,"is_preprint":false},{"pmid":"19159390","id":"PMC_19159390","title":"A protein secreted by the respiratory pathogen Chlamydia pneumoniae impairs IL-17 signalling via interaction with human Act1.","date":"2009","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19159390","citation_count":36,"is_preprint":false},{"pmid":"25710910","id":"PMC_25710910","title":"CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25710910","citation_count":36,"is_preprint":false},{"pmid":"31239234","id":"PMC_31239234","title":"Diabetes induces IL-17A-Act1-FADD-dependent retinal endothelial cell death and capillary degeneration.","date":"2019","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/31239234","citation_count":35,"is_preprint":false},{"pmid":"23116200","id":"PMC_23116200","title":"New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis.","date":"2012","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23116200","citation_count":35,"is_preprint":false},{"pmid":"11864960","id":"PMC_11864960","title":"The ACT-1 plasmid-encoded AmpC beta-lactamase is inducible: detection in a complex beta-lactamase background.","date":"2002","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11864960","citation_count":35,"is_preprint":false},{"pmid":"29981796","id":"PMC_29981796","title":"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29981796","citation_count":34,"is_preprint":false},{"pmid":"24816115","id":"PMC_24816115","title":"Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signaling.","date":"2014","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/24816115","citation_count":33,"is_preprint":false},{"pmid":"31074012","id":"PMC_31074012","title":"RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31074012","citation_count":33,"is_preprint":false},{"pmid":"28971844","id":"PMC_28971844","title":"TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells.","date":"2017","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28971844","citation_count":32,"is_preprint":false},{"pmid":"28053087","id":"PMC_28053087","title":"Targeting TRAF3IP2 by Genetic and Interventional Approaches Inhibits Ischemia/Reperfusion-induced Myocardial Injury and Adverse Remodeling.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28053087","citation_count":29,"is_preprint":false},{"pmid":"31630418","id":"PMC_31630418","title":"IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation.","date":"2019","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31630418","citation_count":29,"is_preprint":false},{"pmid":"20662069","id":"PMC_20662069","title":"The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20662069","citation_count":29,"is_preprint":false},{"pmid":"11014803","id":"PMC_11014803","title":"Suppressors of mdm20 in yeast identify new alleles of ACT1 and TPM1 predicted to enhance actin-tropomyosin interactions.","date":"2000","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11014803","citation_count":29,"is_preprint":false},{"pmid":"27040306","id":"PMC_27040306","title":"TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27040306","citation_count":28,"is_preprint":false},{"pmid":"30882006","id":"PMC_30882006","title":"STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30882006","citation_count":28,"is_preprint":false},{"pmid":"23872479","id":"PMC_23872479","title":"TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23872479","citation_count":28,"is_preprint":false},{"pmid":"20660351","id":"PMC_20660351","title":"An atopic dermatitis-like skin disease with hyper-IgE-emia develops in mice carrying a spontaneous recessive point mutation in the Traf3ip2 (Act1/CIKS) gene.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20660351","citation_count":28,"is_preprint":false},{"pmid":"33928261","id":"PMC_33928261","title":"FYN-TRAF3IP2 induces NF-κB signaling-driven peripheral T cell lymphoma.","date":"2021","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33928261","citation_count":27,"is_preprint":false},{"pmid":"30892082","id":"PMC_30892082","title":"MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling.","date":"2019","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30892082","citation_count":27,"is_preprint":false},{"pmid":"30021197","id":"PMC_30021197","title":"MiR-298 Exacerbates Ischemia/Reperfusion Injury Following Ischemic Stroke by Targeting Act1.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30021197","citation_count":27,"is_preprint":false},{"pmid":"21948371","id":"PMC_21948371","title":"Function of Act1 in IL-17 family signaling and autoimmunity.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/21948371","citation_count":26,"is_preprint":false},{"pmid":"17684298","id":"PMC_17684298","title":"A role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling.","date":"2007","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/17684298","citation_count":26,"is_preprint":false},{"pmid":"33941656","id":"PMC_33941656","title":"Identification of a Long Noncoding RNA TRAF3IP2-AS1 as Key Regulator of IL-17 Signaling through the SRSF10-IRF1-Act1 Axis in Autoimmune Diseases.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33941656","citation_count":26,"is_preprint":false},{"pmid":"16480328","id":"PMC_16480328","title":"Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients.","date":"2006","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/16480328","citation_count":26,"is_preprint":false},{"pmid":"24416204","id":"PMC_24416204","title":"TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behçet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416204","citation_count":26,"is_preprint":false},{"pmid":"28274739","id":"PMC_28274739","title":"Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28274739","citation_count":26,"is_preprint":false},{"pmid":"34140493","id":"PMC_34140493","title":"Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34140493","citation_count":26,"is_preprint":false},{"pmid":"14682614","id":"PMC_14682614","title":"Multiple conserved 5' elements are required for high-level pollen expression of the Arabidopsis reproductive actin ACT1.","date":"2003","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14682614","citation_count":25,"is_preprint":false},{"pmid":"33748112","id":"PMC_33748112","title":"Downregulation of Macrophage-Specific Act-1 Intensifies Periodontitis and Alveolar Bone Loss Possibly via TNF/NF-κB Signaling.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33748112","citation_count":24,"is_preprint":false},{"pmid":"22581863","id":"PMC_22581863","title":"CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22581863","citation_count":24,"is_preprint":false},{"pmid":"27097970","id":"PMC_27097970","title":"Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.","date":"2016","source":"Radiation oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27097970","citation_count":23,"is_preprint":false},{"pmid":"12943667","id":"PMC_12943667","title":"Role of the adaptor protein CIKS in the activation of the IKK complex.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12943667","citation_count":23,"is_preprint":false},{"pmid":"1986221","id":"PMC_1986221","title":"A chicken beta-actin gene can complement a disruption of the Saccharomyces cerevisiae ACT1 gene.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1986221","citation_count":23,"is_preprint":false},{"pmid":"21643828","id":"PMC_21643828","title":"Evolution of vertebrate immunity: sequence and functional analysis of the SEFIR domain family member Act1.","date":"2011","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21643828","citation_count":22,"is_preprint":false},{"pmid":"31292894","id":"PMC_31292894","title":"Chronic Mucocutaneous Candidiasis in an Adolescent Boy Due to a Novel Mutation in TRAF3IP2.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31292894","citation_count":22,"is_preprint":false},{"pmid":"25024377","id":"PMC_25024377","title":"The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25024377","citation_count":20,"is_preprint":false},{"pmid":"29080697","id":"PMC_29080697","title":"Upregulation of miR-215 exerts neuroprotection effects against ischemic injury via negative regulation of Act1/IL-17RA signaling.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/29080697","citation_count":20,"is_preprint":false},{"pmid":"27466370","id":"PMC_27466370","title":"Cardiac-restricted Overexpression of TRAF3 Interacting Protein 2 (TRAF3IP2) Results in Spontaneous Development of Myocardial Hypertrophy, Fibrosis, and Dysfunction.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27466370","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51757,"output_tokens":8243,"usd":0.139458},"stage2":{"model":"claude-opus-4-6","input_tokens":12199,"output_tokens":4040,"usd":0.242993},"total_usd":0.382451,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Act1/CIKS (TRAF3IP2) directly interacts with NEMO/IKKγ and activates IKK and SAPK/JNK kinases, functioning as an adaptor that connects upstream signals to NF-κB and AP-1 activation pathways.\",\n      \"method\": \"Molecular cloning, co-immunoprecipitation, reporter assays, dominant-negative kinase mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated independently by two groups (PMID:10962024 and PMID:10962033) with co-IP and functional reporter assays\",\n      \"pmids\": [\"10962024\", \"10962033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Act1 (TRAF3IP2) directly associates with IL-17 receptor via homotypic SEFIR domain interaction and is an essential membrane-proximal adaptor for IL-17R signaling, mediating NF-κB activation and inflammatory gene induction.\",\n      \"method\": \"Co-immunoprecipitation, Act1-deficient fibroblasts, cytokine/chemokine expression assays, NF-κB reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus genetic loss-of-function with defined signaling phenotype, replicated across multiple labs\",\n      \"pmids\": [\"17035243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"After IL-17 stimulation, Act1 is recruited to IL-17R via the SEFIR domain, then recruits TAK1 and the E3 ubiquitin ligase TRAF6 to mediate downstream NF-κB activation. Act1 deficiency abolishes IL-17-induced inflammation in vivo.\",\n      \"method\": \"Co-immunoprecipitation, Act1-deficient primary astroglial and gut epithelial cells, in vivo EAE and colitis models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, in vitro and in vivo, replicated across labs\",\n      \"pmids\": [\"17277779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Act1 associates with and activates IκB kinase (IKK), leading to liberation of NF-κB from IκB, and also activates JNK.\",\n      \"method\": \"cDNA isolation using NF-κB-dependent selectable marker, co-immunoprecipitation, kinase assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical assay, independently replicated\",\n      \"pmids\": [\"10962024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Act1 is a U-box E3 ubiquitin ligase that, through the Ubc13-Uev1A E2 complex, mediates K63-linked ubiquitination of TRAF6 at lysine-124. U-box mutations abolish this activity and impair IL-17-dependent signaling.\",\n      \"method\": \"In vitro ubiquitination assay, U-box point mutagenesis, Act1-/- MEF reconstitution, site-directed mutagenesis of TRAF6 K124\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of E3 ligase activity plus mutagenesis of both enzyme and substrate\",\n      \"pmids\": [\"19825828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Act1 selectively interacts with TRAF6 (but not other TRAF family members) through its N-terminal domain, and this interaction mediates Act1-induced NF-κB activation; IL-1-induced NF-κB is inhibited by excess Act1.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, dominant-negative TRAF6, NF-κB reporter assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus functional reporter with dominant-negative, replicated in subsequent studies\",\n      \"pmids\": [\"12459498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Act1 is recruited to CD40 receptor in epithelial cells upon CD40L stimulation, interacts with TRAF3, and mediates CD40-induced NF-κB activation and protection from CD40L-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of endogenous Act1 with CD40, Act1 transfection into Act1-negative C33A cells, NF-κB reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP with endogenous proteins plus gain-of-function reconstitution\",\n      \"pmids\": [\"12089335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Act1 functions as a negative regulator of CD40- and BAFF-mediated B cell survival; Act1-deficient B cells show enhanced IκB phosphorylation, NF-κB2 processing, and JNK/ERK/p38 activation upon CD40 and BAFF stimulation. Act1 is recruited to CD40 and BAFFR indirectly via TRAF3.\",\n      \"method\": \"Act1-deficient mice and B cell-specific Act1 KO, Act1/CD40 and Act1/BAFF double-KO epistasis, signaling assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double-KO mice and multiple biochemical signaling readouts\",\n      \"pmids\": [\"15485634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CIKS/Act1 forms homo-oligomers, interacts with NEMO/IKKγ, and is recruited to the IKK complex upon cell stimulation; oligomerization and IKK recruitment are necessary but not sufficient for NF-κB activation, indicating a second regulatory step.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple domain deletion mutants with co-IP and functional assays\",\n      \"pmids\": [\"10962033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Act1/CIKS is essential for all IL-17-induced immediate-early genes in primary fibroblasts. A novel N-terminal subdomain of CIKS is necessary and sufficient for interaction with TRAF6 and NF-κB activation; decoy peptides blocking CIKS-TRAF6 interaction inhibit IL-17 signaling.\",\n      \"method\": \"Act1-deficient primary mouse embryo fibroblasts, deletion mutagenesis, co-immunoprecipitation, NF-κB reporter, decoy peptide assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping, co-IP, and functional decoy peptide with multiple gene expression readouts\",\n      \"pmids\": [\"21335551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The CC' loop of the Act1 SEFIR domain directly binds IL-17RA and is required for Act1-IL-17RA interaction; deletion of the CC' loop abolishes this interaction. A cell-permeable CC' loop decoy peptide inhibits IL-17- and IL-25-induced pulmonary inflammation in mice.\",\n      \"method\": \"Deletion mutagenesis, surface plasmon resonance, co-immunoprecipitation, in vivo mouse lung inflammation model\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — SPR direct binding plus mutagenesis plus in vivo functional validation\",\n      \"pmids\": [\"22045852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A biallelic T536I missense mutation in the Act1 SEFIR domain in humans abolishes homotypic Act1-IL-17R interaction without affecting Act1 homodimerization, causing failure to respond to IL-17A, IL-17F, and IL-17E, resulting in chronic mucocutaneous candidiasis.\",\n      \"method\": \"Patient fibroblast signaling assays, co-immunoprecipitation of endogenous proteins, genetic mapping\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human inborn error with direct biochemical validation of mechanism in patient cells\",\n      \"pmids\": [\"24120361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The psoriasis-associated Act1 D10N variant is defective in interaction with the molecular chaperone Hsp90, leading to global loss of Act1 function; Act1 is a client protein of Hsp90.\",\n      \"method\": \"Co-immunoprecipitation of Act1 with Hsp90, Act1-D10N fibroblast signaling assays, Act1-deficient mouse skin phenotype\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP of client-chaperone interaction, functional validation in patient-variant cells and in vivo mouse model\",\n      \"pmids\": [\"23202271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The psoriasis-associated coding variant D10N (rs33980500) of TRAF3IP2/Act1 shows reduced binding to TRAF6 in functional assays, suggesting altered modulation of immunoregulatory signals.\",\n      \"method\": \"Functional binding assays (co-immunoprecipitation), genome-wide association study with functional follow-up\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP binding assay from single study\",\n      \"pmids\": [\"20953186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TBK1 and IKKi phosphorylate Act1 on serine residues (including Ser311 by IKKi and three additional Ser sites by TBK1), inhibiting Act1-TRAF6 association and consequently suppressing IL-17R-mediated NF-κB activation; TRAF6 (but not TRAF3) is required for IL-17-induced TBK1 activation and its association with Act1.\",\n      \"method\": \"In vitro kinase assays, site-directed mutagenesis of Ser sites, co-immunoprecipitation, NF-κB reporter\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus mutagenesis plus co-IP epistasis\",\n      \"pmids\": [\"22851696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Persistent IL-17 stimulation induces phosphorylation-dependent Lys48-linked polyubiquitination and degradation of Act1 by SCF(β-TrCP) E3 ubiquitin ligase complexes (containing β-TrCP1 or β-TrCP2), providing a desensitization mechanism for IL-17R signaling.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative β-TrCP, siRNA knockdown, ubiquitination assays in HeLa cells\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, dominant-negative, and siRNA with multiple orthogonal readouts\",\n      \"pmids\": [\"22045853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Act1 binds and stabilizes inflammatory mRNAs (e.g., Cxcl1) through its SEFIR domain binding to a stem-loop structure (SEFIR-binding element, SBE) in the 3'UTR. Act1 assembles three distinct RNA-protein complexes (RNPs) that prevent mRNA decay in the nucleus, inhibit decapping in P bodies, and promote translation.\",\n      \"method\": \"RNA immunoprecipitation, RNA aptamer competition, Act1 SEFIR domain-RNA binding assays, fractionation, in vivo mouse inflammation models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct RNA-protein binding assay, multiple RNP characterization methods, in vivo aptamer validation\",\n      \"pmids\": [\"29563620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HuR RNA-binding protein is required for IL-17-induced Act1-mediated mRNA stabilization of CXCL1 and CXCL5; Act1 mediates K63-linked polyubiquitination of HuR, which is required for HuR binding to CXCL1 mRNA and for mRNA stabilization.\",\n      \"method\": \"HuR-deficient cells, co-immunoprecipitation, sucrose gradient polysome fractionation, HuR lung epithelial deletion mouse model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and biochemical dissection of ubiquitination event with in vivo validation\",\n      \"pmids\": [\"23772036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The SEFIR domain of IL-17RA has a 2.3 Å crystal structure; helix αC within the SEFIR domain is critical for interaction with Act1 and IL-17-stimulated gene expression, establishing that heterotypic SEFIR-SEFIR interaction via αC helix is the conserved mechanism for IL-17 signaling.\",\n      \"method\": \"X-ray crystallography (2.3 Å), mutagenesis of αC helix, gene expression assay\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional mutagenesis\",\n      \"pmids\": [\"24816115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIKS/Act1 forms homo-oligomers and requires a second level of regulation beyond NEMO/IKKγ binding for NF-κB activation; a deletion mutant that oligomerizes and binds NEMO but lacks the additional region fails to activate NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab with domain mapping and co-IP, moderate evidence\",\n      \"pmids\": [\"12943667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Act1 is an essential signaling molecule for IL-25 (IL-17E) receptor signaling; Act1 deficiency abolishes IL-25-induced Th2 cytokine expression and pulmonary eosinophilia, and Act1 in epithelial cells is required for both IL-17-induced neutrophilia and IL-25-induced eosinophilia.\",\n      \"method\": \"Act1-deficient mice, epithelial cell-specific Act1 knockout, allergic pulmonary inflammation model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic deletion with defined cellular phenotype, replicated by two independent groups\",\n      \"pmids\": [\"19155512\", \"19155511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Act1 in neuroectoderm-derived CNS-resident cells (specifically astrocytes and NG2+ glia) is required for IL-17-mediated recruitment of lymphocytes, neutrophils, and macrophages in EAE; Act1 deficiency in astrocytes impairs IL-17-mediated inflammatory gene induction.\",\n      \"method\": \"Cell-type-specific conditional Act1 knockout mice, EAE model, inflammatory mediator expression assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional cell-type-specific KO with defined in vivo phenotype, replicated\",\n      \"pmids\": [\"20303295\", \"23995070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The Chlamydia pneumoniae inclusion membrane protein CP0236 binds directly to Act1, sequesters Act1 away from the IL-17 receptor upon IL-17A stimulation, and thereby inhibits NF-κB activation in infected cells.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation of ectopic CP0236 with endogenous Act1, immunofluorescence localization, NF-κB activation assay\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with endogenous protein plus functional signaling readout, single lab\",\n      \"pmids\": [\"19159390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FYN-TRAF3IP2 is a recurrent oncogenic gene fusion in angioimmunoblastic T cell lymphoma and PTCL-NOS that leads to aberrant NF-κB signaling downstream of T cell receptor activation; expression in hematopoietic progenitors induces NF-κB-driven T cell transformation in mice.\",\n      \"method\": \"RNA sequencing fusion discovery, hematopoietic progenitor transduction mouse model, IKK inhibitor treatment in vitro and in vivo\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model plus pharmacologic IKK inhibition, replicated in independent cohort\",\n      \"pmids\": [\"33928261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FYN-TRAF3IP2 and KHDRBS1-LCK fusions activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinical drugs targeting these pathways.\",\n      \"method\": \"RNA sequencing, ex vivo and in vivo experiments in PTCL models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ex vivo and in vivo functional validation, single lab\",\n      \"pmids\": [\"34140493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Act1 functions as a negative regulator in T and B cells via direct inhibition of STAT3; Act1 deficiency (but not Il17ra, Il17rc, or Il17rb deficiency) results in hyper IL-23- and IL-21-induced STAT3 activation. Mass spectrometry detected an Act1-STAT3 complex.\",\n      \"method\": \"Mass spectrometry (interactome), STAT3 activation assays in Act1-/- and single receptor KO T and B cells, in vivo autoimmune disease models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified complex, genetic epistasis with multiple receptor KOs, defined signaling phenotype\",\n      \"pmids\": [\"30013031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Syk kinase is an upstream regulator in IL-17A signaling; Syk interacts with TRAF6 and Act1 under IL-17A stimulation, and Syk inhibition diminishes Act1-TRAF6 interaction and TRAF6 K63-linked polyubiquitination, reducing CCL20 expression in keratinocytes.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, pharmacological Syk inhibition, ubiquitination assay, promoter activity assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus functional epistasis, single lab\",\n      \"pmids\": [\"25202827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-17 stimulation promotes formation of a CIKS/Act1-DDX3X complex requiring the DDX3X helicase domain (but not its ATPase activity); this complex stabilizes Zc3h12a mRNA. IKKε, TRAF2, and TRAF5 are also required for this IL-17-induced mRNA stabilization.\",\n      \"method\": \"Co-immunoprecipitation, DDX3X knockdown, mRNA stability assays, direct RNA-binding assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus direct RNA binding plus functional mRNA stability readout, single lab\",\n      \"pmids\": [\"25710910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAF3IP2 mediates oxLDL-induced endothelial cell death via Nox2/superoxide-dependent upregulation of TRAF3IP2, IKK/p65, and JNK/c-Jun activation; TRAF3IP2 knockdown attenuates this death and vasorelaxation impairment ex vivo.\",\n      \"method\": \"siRNA knockdown, Nox2 inhibition, ex vivo aortic ring relaxation, cell death assays\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — siRNA plus pharmacological inhibition with defined phenotypic readout, single lab\",\n      \"pmids\": [\"24561578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CIKS/TRAF3IP2 mediates angiotensin-II-induced IKK/NF-κB and JNK/AP-1 activation in cardiomyocytes, functioning as a scaffold protein binding to IKK and JNK; CIKS-null mice are protected from Ang-II-induced cardiac hypertrophy and fibrosis despite similar blood pressure increases.\",\n      \"method\": \"CIKS-null mice, co-immunoprecipitation (CIKS binding to IKK and JNK), siRNA, Ang-II infusion in vivo\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with in vivo cardiac phenotype plus biochemical scaffold function via co-IP\",\n      \"pmids\": [\"22575763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Act1 in IL-17 signaling promotes osteoclastogenesis by stimulating RANKL expression in osteoblastic cells; this requires both the E3 ligase U-box and the SEFIR domain of Act1. Act1-deficient mice are protected from ovariectomy-induced bone loss.\",\n      \"method\": \"Act1-/- mice, osteoblast-specific Act1 reconstitution with U-box and SEFIR domain mutants, RANKL expression assay, ovariectomy bone loss model\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis reconstitution in KO cells plus in vivo disease model\",\n      \"pmids\": [\"22511335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Act1 expression in T cells is required for IL-25-driven Th2 polarization (but not conventional IL-4-driven polarization), including induction of GATA-3 and GFI-1 transcription factors, eosinophilic airway infiltration, and airway hyperresponsiveness.\",\n      \"method\": \"T cell-specific Act1-deficient mice, IL-25 stimulation, Th2 differentiation assays, airway inflammation model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic deletion with defined cellular and molecular phenotype\",\n      \"pmids\": [\"21856933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-17A stimulation recruits MST1 to ACT1 in keratinocytes, reducing MST1-LATS1 interaction and leading to YAP dephosphorylation and activation of the YAP-AREG axis promoting keratinocyte proliferation.\",\n      \"method\": \"Co-immunoprecipitation (MST1 with ACT1), immunofluorescence, siRNA knockdown, HaCaT and primary keratinocyte assays\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP of endogenous proteins plus siRNA functional assay, single lab\",\n      \"pmids\": [\"35304250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-17A induces Act1/FADD-dependent caspase-mediated apoptosis in retinal endothelial cells, contributing to retinal capillary degeneration in diabetes; IL-17A-/- mice show significantly less retinal capillary degeneration.\",\n      \"method\": \"IL-17A-/- diabetic mouse model, ex vivo retinal endothelial cell signaling assays, caspase assay\",\n      \"journal\": \"Journal of diabetes and its complications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic KO mouse model plus ex vivo signaling dissection, single lab\",\n      \"pmids\": [\"31239234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Act1 is an evolutionarily conserved signaling protein; zebrafish Act1 retains TRAF6 binding and NF-κB activation capacity in human cells, and a highly conserved N-terminal motif is critical for TRAF6 binding. The helix-loop-helix and Ufd2-box domains enabling JNK activation have more recent evolutionary origins in higher vertebrates.\",\n      \"method\": \"Evolutionary sequence analysis, zebrafish Act1 expression in human cells, co-immunoprecipitation, NF-κB and JNK reporter assays\",\n      \"journal\": \"Journal of molecular evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — cross-species functional complementation with reporter assays, single lab\",\n      \"pmids\": [\"21643828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The antisense lncRNA TRAF3IP2-AS1 regulates Act1 expression and IL-17A signaling by recruiting SRSF10, which downregulates IRF1, a transcriptional activator of Act1; a psoriasis-susceptible variant A4165G (rs13210247) of TRAF3IP2-AS1 is a gain-of-function mutant that increases Act1 expression.\",\n      \"method\": \"lncRNA knockdown/overexpression, SRSF10 siRNA, IRF1 ChIP, Act1 promoter reporter assay, mouse psoriasis and EAE models\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple molecular methods, single lab, in vivo therapeutic validation\",\n      \"pmids\": [\"33941656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Human ACT1 undergoes alternative splicing producing two isoforms; both are Hsp90 client proteins, but ACT1-D19N has an additional Hsp90 binding site from the nine extra amino acids absent in ACT1-D10N. ACT1-D10N fails to transduce IL-17 signals, while ACT1-D19N is fully responsive. The two isoforms are differentially expressed in fibroblasts versus T cells.\",\n      \"method\": \"Co-immunoprecipitation with Hsp90, IL-17 signaling assays in ACT1(D10N/D10N) fibroblasts and T cells, isoform-specific expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP and signaling assays in human cells with variant proteins, single lab\",\n      \"pmids\": [\"25024377\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRAF3IP2/Act1 is a multifunctional cytoplasmic adaptor and U-box E3 ubiquitin ligase that serves as the essential membrane-proximal transducer for IL-17 receptor family signaling: upon IL-17 stimulation, its SEFIR domain (via the CC' loop/αC helix) mediates heterotypic interaction with the IL-17R SEFIR domain, whereupon Act1 recruits TRAF6 (via a conserved N-terminal motif) and mediates K63-linked ubiquitination of TRAF6 to activate TAK1/IKK/NF-κB and JNK/AP-1 pathways; Act1 also directly stabilizes select inflammatory mRNAs by binding 3'UTR stem-loop structures and assembling RNPs; it is regulated by Hsp90 chaperoning, phosphorylation by TBK1/IKKi (which suppresses TRAF6 interaction), and SCF(β-TrCP)-mediated K48-ubiquitin degradation for signal termination; additionally, Act1 acts as a negative regulator in B cells (downstream of CD40/BAFF via TRAF3) and directly inhibits STAT3 in T and B cells, while the oncogenic FYN-TRAF3IP2 fusion drives aberrant NF-κB signaling in peripheral T cell lymphomas.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TRAF3IP2 (Act1/CIKS) is a cytoplasmic adaptor and U-box E3 ubiquitin ligase that functions as the obligate membrane-proximal signal transducer for IL-17 family receptor signaling and additionally acts as a negative regulator of CD40/BAFF and STAT3 pathways in lymphocytes. Upon IL-17 stimulation, Act1 is recruited to IL-17R via heterotypic SEFIR domain interaction (mediated by the CC' loop/αC helix), then recruits TRAF6 through a conserved N-terminal motif and catalyzes K63-linked ubiquitination of TRAF6 at K124 via the Ubc13–Uev1A E2 complex, activating downstream TAK1/IKK/NF-κB and JNK/AP-1 cascades [PMID:17035243, PMID:19825828, PMID:22045852]. Act1 also directly binds stem-loop structures in inflammatory mRNA 3′UTRs through its SEFIR domain, assembling distinct ribonucleoprotein complexes that prevent mRNA decay and promote translation, while its own turnover is governed by Hsp90 chaperoning, TBK1/IKKi-mediated inhibitory phosphorylation, and SCF(β-TrCP)-dependent K48-linked ubiquitination and degradation [PMID:29563620, PMID:23202271, PMID:22851696, PMID:22045853]. Biallelic loss-of-function mutation (T536I) in the SEFIR domain abolishes IL-17R interaction and causes chronic mucocutaneous candidiasis in humans, while the FYN-TRAF3IP2 fusion drives NF-κB-dependent T-cell lymphomagenesis [PMID:24120361, PMID:33928261].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of TRAF3IP2/Act1 as a novel NF-κB- and JNK-activating adaptor established the gene as a signaling node upstream of IKK, resolving whether it was merely a scaffold or an active signal inducer.\",\n      \"evidence\": \"Molecular cloning, co-immunoprecipitation with NEMO/IKKγ, NF-κB and JNK reporter assays by two independent groups\",\n      \"pmids\": [\"10962024\", \"10962033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream receptor triggering Act1 was unknown\", \"Enzymatic activity of Act1 itself not characterized\", \"Homo-oligomerization shown but second regulatory step undefined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstration that Act1 selectively binds TRAF6 (not other TRAFs) through its N-terminus and participates in CD40 signaling via TRAF3 placed it at the intersection of TNF-family and NF-κB pathways, narrowing the search for its functional partnerships.\",\n      \"evidence\": \"Yeast two-hybrid and co-immunoprecipitation of Act1 with TRAF6 and TRAF3; CD40-induced recruitment of endogenous Act1 in epithelial cells\",\n      \"pmids\": [\"12459498\", \"12089335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological receptor linking Act1 to innate immunity remained unknown\", \"Whether Act1 had E3 ligase activity was not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic evidence from Act1-deficient mice revealed an unexpected negative regulatory role in B cells downstream of CD40 and BAFF via TRAF3, resolving conflicting positive/negative functions into a cell-type-dependent model.\",\n      \"evidence\": \"Act1-KO mice and B-cell-specific conditional KO; Act1/CD40 and Act1/BAFF double-KO epistasis\",\n      \"pmids\": [\"15485634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of negative regulation in B cells was unclear\", \"IL-17 receptor connection not yet established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that Act1 directly binds IL-17R via homotypic SEFIR domain interaction and is indispensable for IL-17-induced NF-κB activation identified the long-sought obligate adaptor connecting IL-17 family receptors to downstream inflammatory signaling.\",\n      \"evidence\": \"Co-immunoprecipitation of Act1 with IL-17R, Act1-deficient fibroblasts showing abolished IL-17 responses\",\n      \"pmids\": [\"17035243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SEFIR–SEFIR interaction unknown\", \"E3 ligase activity of Act1 not yet recognized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"In vivo validation using Act1-deficient mice in EAE and colitis models established that Act1-dependent recruitment of TRAF6 and TAK1 to IL-17R is required for inflammatory disease, cementing Act1 as a therapeutic target.\",\n      \"evidence\": \"Act1-KO primary cells plus EAE and dextran sulfate colitis in vivo models\",\n      \"pmids\": [\"17277779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise ubiquitination substrate and linkage type downstream of Act1 unknown\", \"Role in IL-25 signaling not yet tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Biochemical reconstitution showed Act1 is a U-box E3 ubiquitin ligase that catalyzes K63-linked ubiquitination of TRAF6 at K124, resolving whether Act1 was merely an adaptor or an active enzyme in IL-17 signaling.\",\n      \"evidence\": \"In vitro ubiquitination assay with Ubc13–Uev1A, U-box point mutations, TRAF6 K124R mutagenesis, reconstitution in Act1−/− MEFs\",\n      \"pmids\": [\"19825828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Act1 ubiquitinates additional substrates beyond TRAF6 was unknown\", \"Structural basis of U-box activity not determined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extension of Act1's adaptor role to IL-25 (IL-17E) receptor signaling demonstrated that Act1 is a universal transducer for the entire IL-17 receptor family, broadening its function from Th17 to Th2 immunity.\",\n      \"evidence\": \"Act1-KO and epithelial-specific Act1-KO mice in IL-25-driven pulmonary eosinophilia models\",\n      \"pmids\": [\"19155512\", \"19155511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Act1 uses distinct downstream effectors for IL-25 versus IL-17A was unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Structural and peptide-decoy studies mapped the CC' loop of the Act1 SEFIR domain as the critical interface for IL-17RA binding, and identified a conserved N-terminal subdomain sufficient for TRAF6 interaction, providing a molecular framework for therapeutic intervention.\",\n      \"evidence\": \"SPR direct binding, deletion mutagenesis, cell-permeable CC' loop decoy peptide blocking pulmonary inflammation in mice\",\n      \"pmids\": [\"22045852\", \"21335551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution co-crystal structure of Act1–IL-17RA complex not available\", \"SEFIR domain structure of Act1 itself unsolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of SCF(β-TrCP)-mediated K48-linked ubiquitination and proteasomal degradation of Act1 upon persistent IL-17 stimulation revealed the signal-termination mechanism for IL-17R pathway desensitization.\",\n      \"evidence\": \"Co-immunoprecipitation with β-TrCP1/2, dominant-negative β-TrCP, siRNA, ubiquitination assays in HeLa cells\",\n      \"pmids\": [\"22045853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphodegron on Act1 recognized by β-TrCP not precisely mapped\", \"Kinase responsible for degron phosphorylation not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that TBK1/IKKi phosphorylate Act1 on multiple serine residues to inhibit TRAF6 binding established a negative feedback loop within IL-17 signaling, explaining how cells attenuate inflammatory output.\",\n      \"evidence\": \"In vitro kinase assays, site-directed Ser mutagenesis, co-IP showing reduced Act1–TRAF6 association\",\n      \"pmids\": [\"22851696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Temporal dynamics of phosphorylation-dependent versus degradation-dependent attenuation not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of Act1 as an Hsp90 client protein, with the psoriasis-associated D10N variant defective in Hsp90 binding, provided the first mechanism linking a TRAF3IP2 disease-associated variant to protein stability and global loss of function.\",\n      \"evidence\": \"Co-IP of Act1 with Hsp90, D10N fibroblast signaling assays, Act1-deficient mouse skin phenotype\",\n      \"pmids\": [\"23202271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether alternative isoform D19N fully compensates in all tissues was only partially resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of a human biallelic T536I SEFIR domain mutation abolishing Act1–IL-17R interaction and causing chronic mucocutaneous candidiasis provided direct genetic proof that Act1 is essential for human anti-fungal immunity.\",\n      \"evidence\": \"Patient fibroblast signaling assays, co-IP of endogenous proteins, genetic mapping in affected kindred\",\n      \"pmids\": [\"24120361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether T536I affects Act1's RNA-binding or STAT3-inhibitory functions was not examined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that Act1 mediates K63-linked ubiquitination of HuR to promote inflammatory mRNA stabilization revealed a post-transcriptional effector arm beyond NF-κB, expanding Act1's mechanistic repertoire.\",\n      \"evidence\": \"HuR-deficient cells, co-IP, polysome fractionation, HuR lung-epithelial deletion mouse model\",\n      \"pmids\": [\"23772036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of mRNA targets stabilized by Act1–HuR axis unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery that Act1's SEFIR domain directly binds stem-loop structures (SBEs) in inflammatory mRNA 3′UTRs and assembles three distinct RNP complexes for nuclear stabilization, P-body decapping inhibition, and translational promotion established Act1 as a bona fide RNA-binding protein.\",\n      \"evidence\": \"RNA immunoprecipitation, RNA aptamer competition, SEFIR domain–RNA binding assays, in vivo aptamer-based inhibition in mouse inflammation models\",\n      \"pmids\": [\"29563620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SEFIR–RNA interaction unsolved\", \"Full transcriptome-wide set of SBE-containing targets not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that Act1 directly inhibits STAT3 in T and B cells independently of IL-17 receptors resolved the paradox of why Act1-KO but not IL-17R-KO mice develop autoimmunity, establishing a dual positive/negative regulatory logic.\",\n      \"evidence\": \"Mass spectrometry identifying Act1–STAT3 complex, STAT3 phosphorylation assays in Act1−/− and receptor-KO T and B cells, autoimmune disease models\",\n      \"pmids\": [\"30013031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of STAT3 inhibition (direct binding site, competition, or sequestration) not delineated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery of the recurrent FYN-TRAF3IP2 oncogenic fusion in peripheral T-cell lymphomas demonstrated that constitutive Act1-driven NF-κB activation is sufficient for T-cell transformation, directly implicating the gene in cancer pathogenesis.\",\n      \"evidence\": \"RNA-seq fusion detection, hematopoietic progenitor transduction in mouse model, IKK inhibitor rescue in vitro and in vivo\",\n      \"pmids\": [\"33928261\", \"34140493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the fusion retains Act1's RNA-binding or STAT3-inhibitory functions is unknown\", \"Frequency of FYN-TRAF3IP2 across broader lymphoma subtypes incompletely characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the high-resolution structure of the Act1 SEFIR domain and its interface with IL-17RA, the full transcriptome of SBE-containing mRNAs regulated by Act1, the molecular mechanism by which Act1 inhibits STAT3, and whether Act1's E3 ligase activity extends to substrates beyond TRAF6 and HuR.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of Act1 itself\", \"Transcriptome-wide CLIP-seq of Act1 RNA targets not performed\", \"STAT3 inhibition mechanism not biochemically reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [4, 17, 30]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2, 5, 8, 9]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [16, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 2, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 7, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 20, 21, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 7, 25, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 23, 24]}\n    ],\n    \"complexes\": [\n      \"IL-17R signalosome (Act1–IL-17RA–IL-17RC)\",\n      \"Act1–TRAF6 complex\"\n    ],\n    \"partners\": [\n      \"TRAF6\",\n      \"TRAF3\",\n      \"NEMO\",\n      \"IL17RA\",\n      \"HSP90\",\n      \"STAT3\",\n      \"DDX3X\",\n      \"ELAVL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}